TAVR at 5 Years — Rematch or Swan Song for Surgery?
Abstract
To become the first-line treatment for patients with aortic stenosis, 1 transcatheter aortic-valve replacement (TAVR) must not only mitigate periprocedural events but also be as effective as surgical aortic-valve replacement in the long term. Makkar et al. examined this question and report in this issue of the Journal the 5-year outcomes of the Placement of Aortic Transcatheter Valves (PARTNER) 2 cohort A trial, 2 which involved patients at intermediate surgical risk. A total of 2032 patients were stratified according to intended transfemoral or transthoracic access and randomly assigned to undergo TAVR with the second-generation balloon-expandable SAPIEN XT valve or surgical aortic-valve replacement. The trial showed that TAVR was noninferior to surgery with respect to the primary outcome of death from any cause or disabling stroke at 2 years. 3
Domains
Life Sciences [q-bio]Origin | Files produced by the author(s) |
---|